ArticleExperimental & molecular medicine2026
Pericyte-derived exosomal hexokinase 2 promotes retinal neovascularization via non-metabolic ELK3 upregulation.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Retinal neovascularization (RNV) is a major cause of irreversible vision loss worldwide. Although pericyte-endothelial cell cross-talk has been implicated in RNV, the exosome-mediated mechanism underlying this interaction has remained uncharacterized. Here we found that hexokinase 2 (HK2) expression was upregulated in pericytes under hypoxic conditions both in vitro and in vivo. Hypoxic pericytes released exosomes enriched in HK2, which promoted endothelial cell growth in vitro. Conditional deletion of Hk2 in pericytes reduced neovascular tuft formation in mice with oxygen-induced retinopathy, as did inhibition of exosome release with tipifarnib. Notably, exogenous exosomal HK2 restored vascular changes caused by pericyte Hk2 deletion or tipifarnib treatment. RNA sequencing analysis revealed that exosomal HK2 upregulated the ETS transcription factor ELK3 (ELK3), whose expression was elevated in vascular tufts of mice with oxygen-induced retinopathy. Both pericyte Hk2 deletion and tipifarnib treatment suppressed ELK3 expression. Mechanistically, exosomal HK2 bound to and increased mTOR activity, leading to increased ELK3 levels. These findings identify a previously unrecognized non-metabolic role for pericyte-derived exosomal HK2 in RNV and suggest it as a potential therapeutic target.
Identifiers
42988867What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.